LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Afshin Dowlati, R. Donald Harvey, Richard D. Carvajal, Omid Hamid, Samuel J. Klempner, John Kauh, Daniel A. Peterson, Danni Yu, Sonya C. Chapman, Anna M. Szpurka, Michelle Carlsen, Tonya Quinlan, Robert Wesolowski